Investigating a new treatment for cocaine use disorder using a specific drug modulator.
TMP-301, A Negative Allosteric Modulator of type 5 metabotropic glutamate receptors (mGluR5), for Treatment of Cocaine Use Disorder
This study is testing a new medication called TMP-301 to see if it can help people with cocaine use disorder by reducing cravings and the chance of relapse, offering a hopeful new option for those trying to overcome addiction.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tempero Bio, INC. NIH-funded |
| Lab location | 1 site (Oakland, United States) |
| Project ID | NIH-10688133 on NIH RePORTER |
What this research studies
This research focuses on the development of TMP-301, a negative allosteric modulator targeting the mGluR5 receptor, to treat cocaine use disorder (CUD). The approach involves understanding how this drug can alter glutamate signaling, which is often disrupted in individuals with CUD. By potentially reducing cocaine-seeking behaviors and relapse rates, the study aims to provide a new therapeutic option for patients struggling with addiction. The research builds on promising preclinical results and previous clinical findings that suggest similar drugs may help reduce both cocaine and alcohol use.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cocaine use disorder, particularly those who may also struggle with alcohol use disorder.
Not a fit: Patients who do not have cocaine use disorder or those with other unrelated substance use disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that helps reduce cocaine and alcohol use in patients with addiction disorders.
How similar studies have performed: Previous studies have shown success with similar approaches, indicating that targeting the mGluR5 receptor can effectively reduce substance use behaviors.
Where this research is happening
Oakland, United States
- Tempero Bio, INC. — Oakland, United States (Active)
Researchers
- Principal investigator: Meyers, Charles Daniel — Tempero Bio, INC.
- Study coordinator: Meyers, Charles Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.